Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
下一代自体 TIL 癌症疗法:GMP 制造工艺的开发
基本信息
- 批准号:10685604
- 负责人:
- 金额:$ 100万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adaptor Signaling ProteinAddressAdoptive Cell TransfersAdvanced Malignant NeoplasmAffinityAntigen TargetingAntitumor ResponseApplications GrantsAttentionAustraliaAutologous Tumor-Infiltrating LymphocyteAvidityBiological AssayBiological SciencesBiomanufacturingCanadaCell LineCell SurvivalCell TherapyCell surfaceCellsCellular immunotherapyChemotherapy-Oncologic ProcedureClinicalClinical TrialsCollaborationsColoradoContractsCytokine ReceptorsCytotoxic T-LymphocytesDepositionDevelopmentDoseEligibility DeterminationEngineered GeneEngineeringEngraftmentEuropeFutureGenetic EngineeringGoalsHead and neck structureHomingHumanImmuneImmunotherapyInfusion proceduresIntellectual PropertyInterleukin-2JapanLaboratoriesLeadLegal patentLicensingMHC antigenMalignant NeoplasmsMarketingMedicalMethodsModelingMusMyD88 proteinPatientsPenetrationPhasePhase I Clinical TrialsProcessPropertyPublishingRecording of previous eventsRecurrenceRefractoryRegimenResearchRetroviral VectorSafetySignal TransductionSmall Business Innovation Research GrantSolidSolid NeoplasmStressSurvival RateT cell infiltrationT cell responseT-Cell ReceptorT-LymphocyteTechnologyTherapeuticTherapy trialToxic effectTumor AntigensTumor ImmunityTumor PromotionTumor-Infiltrating LymphocytesUniversitiesViral VectorVirusassay developmentcancer clinical trialcancer therapycancer typechemotherapychimeric antigen receptorconditioningcytotoxicdrug developmentengineered T cellsexhaustexhaustionexperienceexperimental studyextracellularfirst-in-humangene delivery systemimmunogenicinterestmanufacturemanufacturing facilitymanufacturing organizationmanufacturing processmelanomamembermouse modelneoantigensneoplastic cellnext generationnoveloperationpatient subsetspre-clinicalprogramsreceptorresponsesafety assessmentsarcomatechnology platformtherapy developmenttumortumor infiltrating lymphocyte therapyviral gene delivery
项目摘要
The overall goal of this Phase II SBIR grant proposal is to research and develop the GMP manufacturing
process for next-generation tumor infiltrating lymphocyte (TIL) cancer therapeutic for solid tumors. In clinical
trials, TIL-based immunotherapies have demonstrated tumor regression and increased survival rates against
different cancer types. Despite these encouraging clinical results, durable antitumor responses are typically
observed in a subset of patients with advanced cancers like melanoma. This stresses the need to develop
more effective TIL-based strategies and to expand efficacy against different cancer types. TIL therapies are
hindered in part by low TIL accumulation into tumors, low persistence, weak T cell receptor (TCR) affinity
and/or avidity as well as the low expression of tumor antigens on the cell’s surface. Additionally, the presence
of suppressive signals on T cells such as Lag3, Tim3, CD39, pose a major obstacle to generating effective and
long-lived antitumor T cell responses. In our published and preliminary studies, activating MyD88 signaling in
human or mouse T cells, increases antitumor activity and prolongs T cell survival. By fusing the high affinity
CD8α (extracellular) to MyD88 (intracellular; CD8α:MyD88) we have developed a novel and universal platform
that activates MyD88 signaling strictly upon the engagement of the TCR with the MHC-antigen on tumor cells.
CD8α:MyD88 expression in TILs cells substantially increases responses to weak and suboptimal levels of
tumor antigens including neoantigens, and in preliminary studies has demonstrated the extraordinary property
of reducing the T cells entry into an ‘exhausted state’. Importantly, the use of the CD8α co-receptor represents
a ‘universal’ approach to enhancing T cell responses, and can be used in patients regardless of the patient’s
HLA type. Through this SBIR Phase II application, we propose the following aims. Aim 1 will research,
develop, and manufacture GMP grade g-retroviral vectors. Here, we will generate high virus titer-producing
CD8a:MyD88-EGFRt PG-13 cell lines, accompanying analytical assays, and manufacture the GMP
CD8a:MyD88-EGFRt g-retroviral vectors. For this aim, we are partnering with a commercial contract
development manufacturing organization (CDMO), Vigene Biosciences to generate GMP viral vectors. In Aim
2, we propose to develop and manufacture GMP CD8a:MYD88 engineered TILs (coR8:AMPTM TILs). In
collaboration with the Gates Manufacturing Facility (GBF) at the University of Colorado Anschutz Medical
Campus (UCAMC) we will conduct process & analytical assay, QC release assay, develop and manufacture of
GMP grade coR8:AMPTM TILs. The successful completion of these aims will lead to the pre-IND and IND filings
with the FDA for a Phase I clinical trial in patients with immune refractory solid tumors. This activity will be
conducted in collaboration with the UCAMC’s Cell Therapy Operations Program (CTOP), Gates
Biomanufacturing Facility, and our team members who have extensive experience in cell therapy drug
development.
这项第二阶段SBIR资助计划的总体目标是研究和发展GMP制造
下一代肿瘤浸润性淋巴细胞(TIL)癌实体瘤的治疗进展。在临床上
试验表明,基于TIL的免疫疗法显示肿瘤消退并提高了存活率。
不同的癌症类型。尽管有这些令人鼓舞的临床结果,持久的抗肿瘤反应通常是
在黑色素瘤等晚期癌症患者中观察到。这强调了发展的必要性
更有效的基于TIL的策略,并扩大对不同类型癌症的疗效。TIL疗法是
部分原因是肿瘤中低TIL积聚、持续时间低、T细胞受体(TCR)亲和力弱
和/或亲和力以及肿瘤抗原在细胞表面的低表达。此外,存在的
T细胞上的抑制信号,如LAG3,TIM3,CD39,构成了产生有效和
长寿的抗肿瘤T细胞反应。在我们已发表的和初步的研究中,激活MyD88信号在
人或小鼠T细胞,增强抗肿瘤活性,延长T细胞存活时间。通过融合高亲和力
CD8α(细胞外)到MyD88(细胞内;CD8α:MyD88)我们开发了一个新颖的通用平台
这在TCR与肿瘤细胞上的MHC抗原结合时严格激活MyD88信号。
CD8α:MyD88在TIL细胞中的表达显著增强对弱和次适水平
肿瘤抗原包括新抗原,并在初步研究中表现出非凡的性质
减少T细胞进入“精疲力竭状态”。重要的是,CD8α共受体的使用代表了
一种增强T细胞反应的“通用”方法,可用于患者,而不考虑患者的
人类白细胞抗原类型。通过这项SBIR第二期申请,我们提出了以下目标。目标一号将进行研究,
研制GMP级g-逆转录病毒载体。在这里,我们将产生高滴度的病毒
CD8a:MyD88-EGFRt PG-13细胞株,附分析检测,并制作GMP
CD8a:MyD88-EGFRt g-逆转录病毒载体。为此,我们与一家商业公司签订了合作合同
开发制造组织(CDMO),Vigene Biosciences,以产生GMP病毒载体。在AIM
2、我们计划研制GMP CD8a:MyD88工程化TIL(CoR8:AMPTM TILs)。在……里面
与科罗拉多大学安舒茨医学院盖茨制造设施(GBF)的合作
校园(UCAMC)我们将进行过程分析测试,QC释放测试,开发和制造
GMP级CoR8:AMPTM瓷砖。这些目标的成功完成将导致IND预审和IND申请
与FDA合作,对免疫难治性实体肿瘤患者进行I期临床试验。这项活动将是
与UCAMC的细胞治疗操作计划(CTOP)合作进行,盖茨
生物制造设施,以及我们在细胞治疗药物方面拥有丰富经验的团队成员
发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD C DUKE其他文献
RICHARD C DUKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD C DUKE', 18)}}的其他基金
Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics
基于全酵母的丙型肝炎疫苗和免疫疗法的开发
- 批准号:
7136398 - 财政年份:2006
- 资助金额:
$ 100万 - 项目类别:
Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics
基于全酵母的丙型肝炎疫苗和免疫疗法的开发
- 批准号:
7274291 - 财政年份:2006
- 资助金额:
$ 100万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Research Grant